文章：

三生物标志物分类器——一种预测结直肠癌患者总生存期的新型简易分子风险评分系统

The 3-Biomarker Classifier—A Novel and Simple Molecular Risk Score Predicting Overall Survival in Patients with Colorectal Cancer

原文发布日期：22 September 2024

DOI: 10.3390/cancers16183223

类型: Article

开放获取: 是

英文摘要：

Introduction: Several new molecular markers in colorectal carcinomas have been discovered; however, classical histopathological predictors are still being used to predict survival in patients. We present a novel risk score, which uses molecular markers, to predict outcomes in patients with colorectal carcinoma. Methods: The immunohistochemistry of tissue micro arrays was used to detect and quantify H2BUB1, RBM3 and Ki-67. Different intensities of staining were categorized for these markers and a score was established. A multivariate analysis was performed and survival curves were established. Results: 1791 patients were evaluated, and multivariate analysis revealed that our risk score, the 3-biomarker classifier, is an independent marker to predict survival. We found a high risk-score to be associated with dismal median survival for the patients. Conclusions: A more personalized score might be able to better discriminate low- and high-risk patients and suggest adjuvant treatment compared to classical pathological staging. Our score can serve as a tool to predict outcomes in patients suffering from colorectal carcinoma.

摘要翻译： 

引言：尽管结直肠癌中已发现多种新型分子标志物，但临床仍依赖传统组织病理学指标预测患者生存期。本研究提出一种基于分子标志物的新型风险评分系统，用于预测结直肠癌患者的临床结局。方法：采用组织芯片免疫组化技术检测并定量H2BUB1、RBM3及Ki-67表达水平，依据染色强度对标志物进行分级并建立评分体系。通过多变量分析构建生存曲线。结果：对1791例患者进行评估，多变量分析显示我们建立的3-生物标志物分类风险评分是预测生存期的独立指标。研究发现高风险评分与患者中位生存期显著缩短相关。结论：相较于传统病理分期，这种更具个性化的评分系统能更有效区分低危与高危患者，并为辅助治疗方案提供参考。本评分系统可作为预测结直肠癌患者临床转归的有效工具。

原文链接：

The 3-Biomarker Classifier—A Novel and Simple Molecular Risk Score Predicting Overall Survival in Patients with Colorectal Cancer